SGO Annual Meeting on Women's Cancer

Preventing Opioid Addiction in Patients With Cancer

March 28th 2018, 7:57pm


Jaron Mark, M.D., a gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses the opioid crisis, and the steps that his institution is taking to combat potential addiction in women who undergo surgery for gynecologic cancer.

Ask an Expert: How Do PARP Inhibitors Work?

March 27th 2018, 7:41pm


PARP inhibitors are generating a lot of excitement in the field of ovarian cancer. But how, exactly, do they work? CURE spoke with one expert to find out.

Gene Testing Can Help Improve Ovarian Cancer Care and Decision Making

March 26th 2018, 10:02pm


Knowing which kind of therapy works best can help in determining the ideal cancer care for patients.

Checkpoint Inhibitors Induce Response, Higher Rates of Side Effects

March 26th 2018, 5:17pm


“There has been a rapid expansion in the use of checkpoint inhibition in many solid tumor types,” lead author Emily Hinchcliff, M.D.

Four Individuals Named Ovarian Cancer Heroes at Inaugural Event

March 24th 2018, 4:29pm


At the inaugural Ovarian Cancer Heroes gala, held in New Orleans ahead of the 49th Society of Gynecologic Oncology Annual Meeting on Women’s Cancers, four individuals — a physician, nurse navigator and two patient-turned-advocates — were awarded for the contributions they have made to increase awareness and advance research and education for ovarian cancer.

Lynparza Improves Progression-Free Survival in BRCA+ Ovarian Cancer

March 15th 2017, 9:19pm


Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improving Survival in BRCA-Proficient Ovarian Cancer

March 15th 2017, 8:20pm


Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.

Jubilee Brown on Genetic Counseling for Patients With Breast and Ovarian Cancer

March 15th 2017, 6:41pm


Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

March 15th 2017, 4:52pm


PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.

Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer

March 15th 2017, 12:37am


Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.